PepGen Ltd shares surge over 115% on positive Phase 2 clinical results for DM1 treatment
PEPG PepGen Inc
$4.61 +92.89%
View chart & analysis → - 1PepGen Ltd shares rose by more than 115% during Tuesday pre-market trading.
- 2The 13-week Phase 2 FREEDOM2-DM1 10 mg/kg cohort showed an average splicing correction rate of 46.5%.
- 3Five out of six participants showed a splicing correction of over 20%.
So what's the key point?
PepGen Ltd received positive results from its treatment trial. The stock price rose by more than 115% following the news.
Source Investing.com +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.